Prime Medicine, Inc. (PRME)
Pre-market:
| Previous close | 6.24 |
| Open | 6.19 |
| Bid | 5.86 x 400 |
| Ask | 5.92 x 200 |
| Day's range | 5.86 - 6.22 |
| 52-week range | 4.11 - 15.75 |
| Volume | |
| Avg. volume | 891,091 |
| Market cap | 706.983M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.18 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 14.10 |
ZacksTop 5 Small-Cap Biotechnology Stocks for a Stable Portfolio
We have narrowed our search to five small-cap biotech stocks with strong potential for the rest of 2024. These are: ARQT, BCYC, CSTL, PRME, LXRX.
ZacksWall Street Analysts Believe Prime Medicine, Inc. (PRME) Could Rally 120.95%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 121% in Prime Medicine, Inc. (PRME). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
GlobeNewswirePrime Medicine to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer will present at two upcoming investor conferences: Jefferies Healthcare Conference: Fireside chat on Wednesday, June 5, 2024, at 1:30 p.m. ET in New York, NY.Goldman Sachs 45th Annual Global Healthcare Conference
